4974
vs
N
Nikkei 225
4974
Over the past 12 months, Takara Bio Inc has underperformed Nikkei 225, delivering a return of -22% compared to the Nikkei 225's +28% growth.
Stocks Performance
4974 vs Nikkei 225
Performance Gap
4974 vs Nikkei 225
Performance By Year
4974 vs Nikkei 225
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Takara Bio Inc
Glance View
Takara Bio, Inc. engages in development and marketing of genetic engineering technologies. The company is headquartered in Kusatsu-Shi, Shiga-Ken and currently employs 1,539 full-time employees. The company went IPO on 2004-12-07. The firm operates in three business segments. Bioindustry Support segment provides reagents for research (genetic engineering reagents, cell engineering reagents, protein engineering reagents), scientific instruments, contract services and license fees for gene related patents to research institutes, such as universities and companies where biotechnology research and development are conducted. Gene Medicine segment provides gene therapy-related development and sale licensing fees and trial products as an application field of genetic engineering technology and cell engineering technology which is core technology cultivated in development of research reagents. Medical Food and Biotechnology segment provides health food and health food research and development services, license fees for health food related patents, as well as license fees for mushrooms.
